Biohaven to present Phase 1 BHV-1530 data at ESMO 2026, signs Regeneron supply deal
The company said its FGFR3-directed ADC showed early tumor reductions, no dose-limiting toxicities, and will be tested with cemiplimab in planned anti-PD-1 combination cohorts.